Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2025)

Vanda Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $3.0 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 75.8% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 75.8% decrease, with the full-year FY2025 number at $3.0 million, down 75.8% from a year prior.
  • Operating Leases hit $3.0 million in Q4 2025 for Vanda Pharmaceuticals, down from $3.4 million in the prior quarter.
  • Over the last five years, Operating Leases for VNDA hit a ceiling of $12.4 million in Q4 2021 and a floor of $3.0 million in Q4 2025.
  • Historically, Operating Leases has averaged $7.9 million across 5 years, with a median of $8.2 million in 2023.
  • Biggest five-year swings in Operating Leases: soared 76.42% in 2024 and later tumbled 75.8% in 2025.
  • Tracing VNDA's Operating Leases over 5 years: stood at $12.4 million in 2021, then decreased by 28.73% to $8.8 million in 2022, then fell by 20.5% to $7.0 million in 2023, then soared by 76.42% to $12.4 million in 2024, then tumbled by 75.8% to $3.0 million in 2025.
  • Business Quant data shows Operating Leases for VNDA at $3.0 million in Q4 2025, $3.4 million in Q3 2025, and $3.9 million in Q2 2025.